HeinOnline is a subscription-based resource containing thousands of academic and legal journals from inception; complete coverage of government documents such as U.S. Statutes at Large, U.S. Code, Federal Register, Code of Federal Regulations, U.S. Reports, and much more. Documents are image-based, fully searchable PDFs with the authority of print combined with the accessibility of a user-friendly and powerful database. For more information, request a quote or trial for your organization below.
![handle is hein.congrecreports/crptxadrj0001 and id is 1 raw text is: AUTHENTICATED
U.S. GOVERNMENT
INFORMATION .
116TH CONGRESS REPORT
2d Session HOUSE OF REPRESENTATIVES 116-695
AFFORDABLE PRESCRIPTIONS FOR PATIENTS THROUGH
PROMOTING COMPETITION ACT OF 2019
DECEMBER 24, 2020.-Committed to the Committee of the Whole House on the State
of the Union and ordered to be printed
Mr. NADLER, from the Committee on the Judiciary,
submitted the following
R E P O R T
[To accompany H.R. 5133]
The Committee on the Judiciary, to whom was referred the bill
(H.R. 5133) to amend the Federal Trade Commission Act to pro-
hibit anticompetitive behaviors by drug product manufacturers,
and for other purposes, having considered the same, reports favor-
ably thereon without amendment and recommends that the bill do
pass.
CONTENTS
Page
Purpose and Sum m ary ............................................................................................ 1
Background and Need for the Legislation ............................................................. 2
H e a rin g s ................................................................................................................... 6
Com m ittee Consideration ........................................................................................ 7
C om m ittee V otes ...................................................................................................... 7
Com m ittee Oversight Findings ............................................................................... 7
New Budget Authority and Tax Expenditures and Congressional Budget Of-
fice C ost E stim ate ............................................................................................... 7
Duplication of Federal Program s ........................................................................... 7
Perform ance Goals and Objectives ......................................................................... 7
A dvisory on E arm ark s ............................................................................................ 8
Section-by-Section A nalysis .................................................................................... 8
Changes in Existing Law Made by the Bill, as Reported ..................................... 10
Purpose and Summary
H.R. 5133, the Affordable Prescriptions for Patients Through
Promoting Competition Act, prohibits product hopping, a par-
ticularly abusive form of anti-competitive conduct used by drug
manufacturers to protect and extend their monopolies on prescrip-
tion drugs. Product hopping occurs when a branded drug manufac-
turer seeks to extend its market exclusivity on a drug for which its
19-006](ViewImageLocal?handle=hein.congrecreports/crptxadrj0001&div=1&collection=&method=preview&ext=.png&size=3)